TWD 30.0
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -29.36 Million TWD | -3911.14% |
2022 | 4.41 Million TWD | -97.3% |
2021 | 23.15 Million TWD | -62.74% |
2020 | 74.14 Million TWD | -29.59% |
2019 | 105.3 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 1.52 Million TWD | 103.02% |
2024 Q1 | -14.71 Million TWD | -150.4% |
2023 Q4 | 27.82 Million TWD | 284.5% |
2023 FY | - TWD | -3911.14% |
2023 Q3 | -15.08 Million TWD | 42.86% |
2023 Q2 | -26.39 Million TWD | -79.05% |
2023 Q1 | -14.74 Million TWD | -511.21% |
2022 FY | - TWD | -97.3% |
2022 Q4 | 3.58 Million TWD | 0.0% |
2021 FY | - TWD | -62.74% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Allied Biotech Corporation | 204.79 Million TWD | 114.341% |
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | 112.709% |
Easywell Biomedicals, Inc. | -85.5 Million TWD | 65.651% |
TTY Biopharm Company Limited | 1.52 Billion TWD | 101.927% |
Synmosa Biopharma Corporation | 1 Billion TWD | 102.911% |
Orient EuroPharma Co., Ltd. | 582.93 Million TWD | 105.038% |
Center Laboratories, Inc. | -175.17 Million TWD | 83.234% |
Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | 194.592% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | 117.036% |
InnoPharmax Inc. | -62.12 Million TWD | 52.722% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | 123.184% |
DV Biomed Co., Ltd. | 407.64 Million TWD | 107.205% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 96.78% |
Handa Pharmaceuticals, Inc. | 802.78 Million TWD | 103.658% |
UniPharma Co., Ltd. | -16.25 Million TWD | -80.688% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | 122.366% |
Alar Pharmaceuticals Inc. | 394.52 Million TWD | 107.444% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | 112.863% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | 24.76% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | 342.019% |
TSH Biopharm Corporation Limited | 99.35 Million TWD | 129.561% |